Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980530 | 0.88 | FFAR1 (0.71) | FFAR1 | |
| SCHEMBL3980533 | 0.88 | FFAR1 (0.71) | FFAR1 | |
| SCHEMBL17754960 | 0.85 | RAB9A (0.51) | KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL3967988 | 0.85 | ABCB11 (0.67) | FFAR1L3MBTL1TSHR | |
| SCHEMBL6484578 | 0.85 | FFAR1 (0.66) | FFAR1KMT2AATML3MBTL1HTT | |
| SCHEMBL5702738 | 0.84 | FFAR1 (0.49) | FFAR1KMT2AATML3MBTL1ALDH1A1 | |
| SCHEMBL12883281 | 0.84 | TNF (0.54) | FFAR1KMT2AL3MBTL1ALDH1A1HTT | |
| SCHEMBL2226074 | 0.83 | L3MBTL1 (0.68) | FFAR1KMT2AATML3MBTL1LDHA | |
| SCHEMBL13140159 | 0.82 | FFAR1 (0.64) | FFAR1ALDH1A1TSHRFFAR4 | |
| SCHEMBL8476326 | 0.82 | FFAR1 (0.53) | FFAR1KMT2AL3MBTL1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200223816-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200223815-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT PHARMACEUTICALS, LLC (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3666268-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | ADT Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2009053443-A2 | INDANE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2009-04-30 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-6387920-B2 | ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE | CHIRON CORPORATION | 2002-05-14 | — | — | US | disclosed |
| CN-1129698-A | Oxazolidinedione derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-08-28 | — | — | CN | disclosed |
| EP-0302603-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4798843-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-17 | — | — | US | disclosed |
| US-4273873-A | BONDING SYNTHETIC FIBRINOLYTIC COMPOUND OR ENZYME | UNITIKA LTD. (JP) | 1981-06-16 | — | — | US | disclosed |
| US-4006243-A | FUNGICIDE, BACTERICIDE, YEAST | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
| US-20200223815-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | FFAR1 2520/4885KMT2A 2337/4885ATM 2097/4885 |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | FFAR1 51/4885KMT2A 2325/4885ATM 4565/4885 |
| US-11130744-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
| US-10981886-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
| US-20200223817-A1 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | KRAS, NRAS, HRAS | FFAR1 2520/4885KMT2A 2337/4885ATM 2097/4885 |
| US-20200223816-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | FFAR1 1810/4885KMT2A 1996/4885ATM 2862/4885 |
| US-10975054-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | FFAR1 1339/4885KMT2A 2861/4885ATM 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.